(RXRX) Recursion Pharmaceuticals, Inc. ANSOFF Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(RXRX) Recursion Pharmaceuticals, Inc. Complete Analysis Pack
Dive Deeper Into the Growth Paths Behind the Analysis
This Recursion Pharmaceuticals, Inc. Ansoff Matrix Analysis maps the company’s growth options across market penetration, market development, product development, and diversification and is used to guide strategic, investment, or R&D decisions; this page already contains a real preview of the analysis so you can review style and substance before buying. Purchase the full version to receive the complete, ready-to-use Ansoff Matrix tailored to Recursion.
Market Penetration
REC-994 Phase IIa cerebral cavernous malformation
REC-994’s Phase IIa cerebral cavernous malformation program is a clear market penetration move: Recursion is deepening its position in the same rare-disease space with the same asset. The focus is now on enrollment, site execution, and data quality, not new-market expansion. That fits a current development market where speed and trial delivery drive visibility.
REC-3599 Phase I GM2 gangliosidosis
REC-3599’s Phase I program in GM2 gangliosidosis supports market penetration by deepening Recursion Pharmaceuticals, Inc.’s presence in an ultra-rare neurology niche without changing the asset. GM2 gangliosidosis is an ultra-rare lysosomal storage disease, so even one ongoing study can strengthen scientific visibility, site relationships, and patient-finding capability. Continued dose, safety, and biomarker progress in Phase I helps Recursion build trust around the same molecule and broaden its footprint in rare CNS disorders.
REC-2282 neurofibromatosis type 2
REC-2282 deepens Recursion Pharmaceuticals, Inc.'s reach in the NF2 rare-disease niche, where NF2 affects about 1 in 25,000 to 33,000 people. As a current clinical-stage asset, it keeps the Company in the same patient pool while it builds treatment use, site know-how, and investigator loyalty. That matters in a small market, where even one more enrolled trial can strengthen access and retention.
REC-4881 familial adenomatous polyposis
REC-4881 gives Recursion Pharmaceuticals, Inc. a clear foothold in familial adenomatous polyposis, a rare GI market with roughly 1 in 8,000 to 1 in 10,000 people affected. Market penetration here means putting more development weight behind one existing asset, not expanding into a new disease area.
- Strengthens an existing rare-disease position
- Targets a narrow, clinically defined market
- Penetration = deeper program investment
- Fits Recursion’s oncology and GI focus
Current clinical-stage rare-disease portfolio
Recursion Pharmaceuticals, Inc. is using its current Phase I and Phase IIa rare-disease assets as the base for market share gains in development-stage orphan markets. The portfolio covers 4 programs: cerebral cavernous malformation, GM2 gangliosidosis, NF2, and familial adenomatous polyposis, so capital stays focused on existing demand pockets before wider expansion.
- 4 clinical rare-disease assets
- Phase I and Phase IIa base
- Focus: current markets first
- Expansion comes after validation
Recursion Deepens Its Grip on Ultra-Rare Disease Markets
Recursion Pharmaceuticals, Inc. is using its 4 ongoing rare-disease programs to push deeper into the same patient pools, not enter new ones. That is market penetration: more focus on current assets, tighter site execution, and stronger investigator reach in ultra-rare markets like NF2 and FAP.
| Asset | Stage | Market |
|---|---|---|
| REC-994 | Phase IIa | CCM |
| REC-3599 | Phase I | GM2 |
What is included in the product
Detailed Word Document
Outlines Recursion Pharmaceuticals, Inc.’s growth options across existing and new products and markets
Editable Excel File
Provides a quick Ansoff Matrix view for Recursion Pharmaceuticals, Inc. to simplify growth strategy decisions across drugs, data, and new markets.
Reference Sources
Provides a concise, traceable bibliography of primary and reputable sources to validate Recursion Pharmaceuticals' Ansoff Matrix growth assumptions for faster due diligence.
Market Development
Bayer AG collaboration
Recursion Pharmaceuticals, Inc. uses its Bayer AG partnership to push beyond Salt Lake City and reach Bayer’s global development network. The alliance, announced as a deal worth up to $1.5 billion in milestones and royalties, lets Recursion keep its core AI platform and pipeline while using a much larger external channel. That widens reach without adding new core assets or sites.
Takeda Pharmaceutical Company Limited collaboration
Takeda Pharmaceutical Company Limited collaboration can widen Recursion Pharmaceuticals, Inc. market development by adding partner-led R&D routes to its existing pipeline, so each program can move through more channels than Recursion could fund alone. Recursion already uses an external collaboration model, and Takeda helps extend that playbook across more assets, which matters as the company targets broader development and commercialization reach. The value is scale: more partnered programs, more shots on goal, and more non-dilutive capital tied to shared R&D execution.
University of Utah Research Foundation collaboration
Recursion Pharmaceuticals, Inc. uses the University of Utah Research Foundation collaboration to widen academic-market reach through the University of Utah network, adding another translational R&D channel without changing its core platform. In 2025, Recursion reported $58.0 million in revenue and $619.5 million in cash, giving it room to push the platform into new research settings.
Ohio State Innovation Foundation collaboration
Ohio State Innovation Foundation strengthens Recursion Pharmaceuticals, Inc.’s market development by widening access to a major academic and clinical ecosystem. One large research partner can improve platform reach, since Ohio State helps open more translational studies, patient links, and discovery channels. This fits Ansoff market development: same platform, broader institutional footprint.
- Expands reach through one major university partner
- Supports more research and clinical pathways
- Scales the same platform without new core tech
Chromaderm, Inc. collaboration
Chromaderm, Inc. gives Recursion Pharmaceuticals, Inc. a new external development partner, which fits Ansoff’s market development move. The deal widens discovery and validation beyond Recursion’s core headquarters base, so its AI-enabled drug engine can reach more use cases and partners. This matters because Recursion can extend existing capabilities into a broader network without building every new path in-house.
New partner, not a new product.
Expands discovery outside core labs.
Builds wider validation access.
Recursion Scales AI Drug Reach Through Partner Networks
Recursion Pharmaceuticals, Inc. drives market development by using partner networks like Bayer AG and Takeda Pharmaceutical Company Limited to push the same AI drug platform into more geographies and research channels. In 2025, Recursion reported $58.0 million revenue and $619.5 million cash, giving it room to scale external reach without new core sites.
| Metric | 2025 |
|---|---|
| Revenue | $58.0 million |
| Cash | $619.5 million |
| Market development lever | Partner networks |
Preview Before You Purchase
Recursion Pharmaceuticals, Inc. Reference Sources
This is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report you'll get; purchase unlocks the complete, editable version with detailed market, product, risk, and strategic recommendations tailored to Recursion Pharmaceuticals, Inc.
Product Development
REC-65029 HRD-negative ovarian cancer
REC-65029 HRD-negative ovarian cancer is a new oncology molecule in Recursion Pharmaceuticals, Inc.'s pipeline, so it fits Product Development in the Ansoff Matrix by extending a current cancer focus into a defined tumor segment. HRD-negative ovarian cancer remains a large unmet need, with about 314,000 new ovarian cancer cases and 207,000 deaths worldwide in 2022. This adds depth to Recursion Pharmaceuticals, Inc.'s oncology set without moving into a new market.
REC-2029 wnt-mutant hepatocellular carcinoma
REC-2029 widens Recursion Pharmaceuticals, Inc.'s oncology portfolio by adding a targeted hepatocellular carcinoma program, so it is clear product expansion. The wnt-mutant liver cancer focus fits the Company Name's existing cancer-first development model and keeps it inside a familiar biology lane. This supports a broader pipeline strategy without stepping outside its core oncology focus.
REC-14221 solid and hematological malignancies
REC-14221 broadens Recursion Pharmaceuticals, Inc.’s oncology mix by targeting both solid and hematological malignancies, so it can fit more cancer settings with one asset. In Ansoff terms, this is product development: a new product for an existing therapeutic market. The bigger reach across solid tumors and blood cancers can deepen market coverage without leaving oncology.
REC-64151 KRAS/STK11 mutant non-small cell lung cancer
REC-64151 adds depth to Recursion Pharmaceuticals, Inc.’s precision oncology push by targeting a KRAS/STK11-mutant NSCLC subgroup tied to immune checkpoint resistance. NSCLC is about 85% of lung cancers, and KRAS mutations show up in roughly 25% of lung adenocarcinomas, with STK11 often marking poorer immunotherapy response.
In Ansoff terms, this is a product-development move: a new oncology asset for an existing cancer market. It broadens the pipeline with a biomarker-defined program that can support more selective trial design and cleaner clinical signals.
- Precision oncology depth
- Checkpoint-resistant NSCLC niche
- New product, current market
REC-648918 anti-tumor immunity
REC-648918 is an immuno-oncology extension that aims to boost anti-tumor immunity, fitting Recursion Pharmaceuticals, Inc.'s oncology focus and adding a differentiated asset to its cancer pipeline. With cancer causing about 10 million deaths a year worldwide, immune-focused programs target a huge unmet need and can widen the company's reach beyond core platforms.
- Extends oncology into immuno-oncology
- Targets anti-tumor immune activation
- Adds a differentiated new asset
- Supports a large cancer market
Recursion Expands Its Cancer Pipeline With New Targeted Oncology Assets
Recursion Pharmaceuticals, Inc.’s product development move is to add new oncology assets to an existing cancer base, not to enter a new market. REC-65029, REC-2029, REC-14221, REC-64151, and REC-648918 all widen the pipeline in defined tumor or biomarker groups, including HRD-negative ovarian cancer and KRAS/STK11-mutant NSCLC. That fits a new-product, current-market play.
| Asset | Fit | Key point |
|---|---|---|
| REC-65029 | Product development | HRD-negative ovarian cancer |
| REC-64151 | Product development | KRAS/STK11-mutant NSCLC |
Diversification
REC-3964 C. difficile colitis
REC-3964 pushes Recursion Pharmaceuticals, Inc. into infectious disease, a clear move beyond its rare-disease and oncology core. C. difficile colitis is a separate market with about 462,000 U.S. infections and 29,300 deaths in 2017, so the asset widens therapeutic spread with a new product in a new area. That makes this a diversification play, not just a pipeline add-on.
REC-64917 neural/systemic inflammation
REC-64917 moves Recursion Pharmaceuticals, Inc. into inflammation biology as a separate market, not just a cancer play. That matters because it broadens the platform beyond its oncology-heavy base and adds a new therapeutic lane with distinct disease biology, target selection, and clinical readouts. In Ansoff terms, it is diversification: a new product class for a new disease area.
REC-3599 GM2 gangliosidosis
REC-3599 pushes Recursion Pharmaceuticals, Inc. into ultra-rare neurology with GM2 gangliosidosis, a separate patient group with its own biology, trial design, and regulatory path. GM2 is inherited, progressive, and often fatal in early childhood, so it opens a distinct market from Recursion’s other rare-disease programs. That broadens exposure across rare-disease segments and lowers reliance on one indication.
REC-2282 neurofibromatosis type 2
REC-2282 in neurofibromatosis type 2 (NF2) moves Recursion Pharmaceuticals, Inc. beyond oncology into a second rare neurological market, and NF2 affects about 1 in 25,000 people. It adds a distinct clinical-development lane while using the same data and AI platform, so disease risk is broader without building a new engine.
- Second rare neuro market beyond oncology
- One platform, broader disease diversification
REC-4881 familial adenomatous polyposis
REC-4881 moves Recursion Pharmaceuticals, Inc. into hereditary gastrointestinal disease, a clear diversification step beyond its cancer and neurology programs. Familial adenomatous polyposis is rare, affecting about 1 in 8,000 to 1 in 10,000 people, so it sits in a distinct market with different clinicians, patients, and trial paths. That broadens Recursion Pharmaceuticals, Inc. across multiple therapeutic classes and lowers single-portfolio concentration.
- New hereditary GI market
- Separate from oncology and neurology
- Supports multi-class diversification
Recursion Expands Beyond Oncology With a Broader, Lower-Risk Pipeline
Recursion Pharmaceuticals, Inc. is using diversification to spread beyond oncology into infectious disease, inflammation, neurology, and hereditary GI disease. REC-3964, REC-64917, REC-3599, REC-2282, and REC-4881 each target a separate market, which lowers single-therapy risk and widens the pipeline. The move is platform-led, but the commercial and clinical bets are now much broader.
| Program | New market | Signal |
|---|---|---|
| REC-3964 | C. difficile | Infectious disease |
| REC-64917 | Inflammation | New therapeutic lane |
| REC-3599 | GM2 | Ultra-rare neurology |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.